All In Biotech

Free tool

FAERS Monitor: Jeuveau

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761085 or its brand name (Jeuveau, Prabotulinumtoxina-Xvfs). Reports on generic versions are filed under their own applications.

Reports

3,779

Serious

61

2% of reports

Hospitalization

24

Death reported

1

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective1,590
  • off label use1,315
  • therapeutic product effect decreased715
  • drug effect less than expected469
  • headache171
  • injection site pain114
  • patient dissatisfaction with treatment105
  • injection site swelling99
  • eyelid ptosis73
  • inappropriate schedule of product administration72
  • injection site erythema67
  • product preparation issue59
  • injection site pruritus52
  • dizziness45
  • vision blurred43

Reports by year received

View as table
YearReports
20191,156
2020749
2021199
2022175
2023273
2024326
2025406
2026495

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,380 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
patient dissatisfaction with treatmentSignal105320.7264.131,340
drug effect less than expectedSignal469181.9166.881,580
therapeutic product effect decreasedSignal71590.384.562,160
product preparation issueSignal5950.539.22,789
eyelid ptosisSignal7340.332.12,738
off label useSignal1,3158.48.08,883
injection site swellingSignal997.25.9524
drug ineffectiveSignal1,5906.76.58,246
injection site pruritusSignal524.33.3130
injection site erythemaSignal673.02.488
inappropriate schedule of product administrationSignal722.21.848
injection site painSignal1142.11.763
vision blurred431.71.313
headache1711.51.331
dizziness450.50.422

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.